SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 229 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,219,260 | -53.9% | 3,700,000 | 0.0% | 0.00% | -60.0% |
| Q2 2023 | $4,810,000 | -28.4% | 3,700,000 | -3.1% | 0.01% | -28.6% |
| Q1 2023 | $6,721,639 | -43.8% | 3,819,113 | +0.3% | 0.01% | -46.2% |
| Q4 2022 | $11,957,579 | -35.8% | 3,808,146 | +0.1% | 0.01% | -38.1% |
| Q3 2022 | $18,636,000 | +18.7% | 3,803,127 | +0.3% | 0.02% | +31.2% |
| Q2 2022 | $15,704,000 | -28.7% | 3,793,300 | +0.1% | 0.02% | -15.8% |
| Q1 2022 | $22,021,000 | -18.2% | 3,790,235 | +5.7% | 0.02% | +35.7% |
| Q4 2021 | $26,905,000 | -16.8% | 3,587,370 | -0.0% | 0.01% | -22.2% |
| Q3 2021 | $32,332,000 | -25.1% | 3,588,595 | -0.5% | 0.02% | -21.7% |
| Q2 2021 | $43,183,000 | -4.3% | 3,607,551 | +0.2% | 0.02% | 0.0% |
| Q1 2021 | $45,104,000 | -15.2% | 3,599,735 | +5.6% | 0.02% | -11.5% |
| Q4 2020 | $53,182,000 | +84.8% | 3,407,986 | +11.9% | 0.03% | +44.4% |
| Q3 2020 | $28,776,000 | +10.4% | 3,045,026 | +4.7% | 0.02% | -5.3% |
| Q2 2020 | $26,061,000 | +48.4% | 2,908,641 | +5.5% | 0.02% | +26.7% |
| Q1 2020 | $17,560,000 | -15.2% | 2,756,610 | +11.4% | 0.02% | 0.0% |
| Q4 2019 | $20,710,000 | -7.3% | 2,474,188 | +0.2% | 0.02% | -21.1% |
| Q3 2019 | $22,345,000 | -12.3% | 2,468,941 | +4.4% | 0.02% | -17.4% |
| Q2 2019 | $25,466,000 | +13.8% | 2,364,412 | +0.8% | 0.02% | +15.0% |
| Q1 2019 | $22,385,000 | -16.9% | 2,346,344 | +0.1% | 0.02% | -28.6% |
| Q4 2018 | $26,922,000 | -27.3% | 2,345,143 | +7.4% | 0.03% | -15.2% |
| Q3 2018 | $37,027,000 | +47.4% | 2,184,505 | +23.5% | 0.03% | +32.0% |
| Q2 2018 | $25,116,000 | -31.7% | 1,768,741 | -8.6% | 0.02% | -26.5% |
| Q1 2018 | $36,760,000 | +249.3% | 1,934,665 | +201.4% | 0.03% | +277.8% |
| Q4 2017 | $10,525,000 | +65.5% | 641,805 | +51.4% | 0.01% | +50.0% |
| Q3 2017 | $6,358,000 | +91.8% | 423,855 | +12.5% | 0.01% | +100.0% |
| Q2 2017 | $3,315,000 | +75.5% | 376,688 | +3.7% | 0.00% | +50.0% |
| Q1 2017 | $1,889,000 | +66.1% | 363,278 | -2.5% | 0.00% | +100.0% |
| Q4 2016 | $1,137,000 | -38.5% | 372,768 | -6.6% | 0.00% | -50.0% |
| Q3 2016 | $1,848,000 | -19.4% | 399,013 | +0.8% | 0.00% | -33.3% |
| Q2 2016 | $2,294,000 | +3.7% | 395,944 | +8.3% | 0.00% | 0.0% |
| Q1 2016 | $2,212,000 | -22.2% | 365,620 | +17.5% | 0.00% | 0.0% |
| Q4 2015 | $2,842,000 | +60.2% | 311,200 | -1.0% | 0.00% | +50.0% |
| Q3 2015 | $1,774,000 | -61.3% | 314,421 | -23.9% | 0.00% | -50.0% |
| Q2 2015 | $4,580,000 | -10.6% | 412,936 | +26.4% | 0.00% | -20.0% |
| Q1 2015 | $5,125,000 | -32.2% | 326,795 | -34.2% | 0.01% | -28.6% |
| Q4 2014 | $7,556,000 | +68.2% | 496,718 | +19.3% | 0.01% | +75.0% |
| Q3 2014 | $4,491,000 | +106.6% | 416,357 | +192.5% | 0.00% | +100.0% |
| Q2 2014 | $2,174,000 | -31.9% | 142,361 | -19.4% | 0.00% | -33.3% |
| Q1 2014 | $3,192,000 | +377.1% | 176,523 | +265.8% | 0.00% | +200.0% |
| Q4 2013 | $669,000 | +0.3% | 48,258 | -24.1% | 0.00% | 0.0% |
| Q3 2013 | $667,000 | +160.5% | 63,588 | +94.4% | 0.00% | – |
| Q2 2013 | $256,000 | -30.1% | 32,711 | -14.5% | 0.00% | – |
| Q1 2013 | $366,000 | – | 38,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,000,000 | $66,540,000 | 6.69% |
| FIC CAPITAL INC | 787,529 | $8,734,000 | 3.47% |
| RA Capital Management | 1,220,209 | $13,532,000 | 1.36% |
| PRINCETON CAPITAL MANAGEMENT INC | 114,120 | $1,266,000 | 0.67% |
| Perceptive Advisors | 800,000 | $8,872,000 | 0.53% |
| Cormorant Asset Management, LP | 361,000 | $4,003,000 | 0.53% |
| Highlander Capital Management, LLC | 43,500 | $482,000 | 0.43% |
| APEX CAPITAL, LLC | 439,900 | $4,878,000 | 0.42% |
| WASATCH ADVISORS LP | 3,091,386 | $34,283,000 | 0.37% |
| Baker Brothers Advisors | 3,230,932 | $35,831,000 | 0.31% |